| Patent(s) and the Corresponding Patented Drug(s) |
Top |
| World Intellectual Property Organization (WIPO) |
| Patent ID |
WO2017118822 |
| Title |
Multi-Target Compounds with Inhibitory Activity Towards Histone Deacetylases and Tubulin Polymerisation, for Use In The Treatment of Cancer. |
| Abstract |
The present invention relates to the design of new molecules, referred to as ...ulti-target...molecules, having a double pharmacophore and acting both as inhibitors of histone deacetylases (HDAC) and as inhibitors of tubulin polymerisation. The invention also describes the method for synthesising the ...ulti-target...molecules and their use in the treatment of cancer, a pharmaceutical composition comprising at least one ...ulti-target...molecule, and the use of such compositions in the treatment of cancer. |
| Applicant(s) |
Center National De La Recherche Scientifique (Cnrs) |
| Representative Drug(s) |
D04JWR |
Drug Info
|
IC50 = 10000 nM |
[1] |
| Patent ID |
WO2017077008 |
| Title |
Selective Hdac8 Inhibitors and Their Uses. |
| Abstract |
The present invention relates to small molecule compounds based on benzopyrimido- or benzoimidazo-thiazin-imine as well as their (synthesis) intermediates and their use as HDAC inhibitors, in particular HDAC8 inhibitors. The present invention also relates to the use of said compounds in the treatment of cancer and as therapeutic agents for eukaryotic parasites and respective methods of treatment. |
| Applicant(s) |
Hochschule Darmstadt |
| Representative Drug(s) |
D0M0RE |
Drug Info
|
IC50 = 4.1 nM |
[1] |
| Patent ID |
WO2017039726 |
| Title |
Novel Hdac Inhibitors and Methods of Treatment Using The Same. |
| Abstract |
Disclosed herein are novel HDAC inhibitors. The HDAC inhibitors may be used in methods of treating cancer. The HDAC inhibitors may be used in methods of treating a neurological disorder. |
| Applicant(s) |
Uwm Research Foundation, Inc |
| Representative Drug(s) |
D0JB4S |
Drug Info
|
IC50 = 49380 nM |
[1] |
| Patent ID |
WO2017030938 |
| Title |
Heterocyclic Compounds and Uses Thereof. |
| Abstract |
The present disclosure relates to heterocyclic compounds, and pharmaceutical compositions of the same, that are modulators/inhibitors of HDACs, such as HDAC8 and are useful in the treatment of HDAC-associated diseases. |
| Applicant(s) |
Incyte Corporation |
| Representative Drug(s) |
D04UGJ |
Drug Info
|
IC50 <= 50 nM |
[1] |
| Patent ID |
WO2016020369 |
| Title |
Novel Hdac6 Inhibitors and Their Uses. |
| Abstract |
The present invention relates to small molecule compounds and their use as HDAC inhibitors and in the treatment of various diseases, such as cancer. The present invention further relates to methods of synthesizing the compounds and methods of treatment. H L(HA), H is a head group selected from (head group 1), (head group 2), (head group 3), (head group 4), (head group 5) and (head group 6). |
| Applicant(s) |
Universitt Regensburg |
| Representative Drug(s) |
D00HXJ |
Drug Info
|
IC50 = 249 nM |
[1] |
| Patent ID |
WO2016018795 |
| Title |
Histone Deacetylase Inhibitors. |
| Abstract |
Provided herein are brain penetrant histone deacetylase (HDAC) inhibitors useful for treating diseases or disorders associated with HDAC. An exemplary HDAC inhibitor provided herein exhibits a brain-to-plama ratio of 20: 1. Pharmaceutical compositions comprising HDAC inhibitors and methods for treating diseases associated with HDAC are also provided. |
| Applicant(s) |
The General Hospital Corporation |
| Representative Drug(s) |
D0DI9S |
Drug Info
|
IC50 > 15000 nM |
[1] |
| Patent ID |
WO2015175813 |
| Title |
Heterocyclic Hydroxamic Acids As Protein Deacetylase Inhibitors and Dual Protein Deacetylase-Protein Kinase Inhibitors and Methods of Use Thereof. |
| Abstract |
The present invention relates to novel hydroxamic acids which are specific histone deacetylase (HDAC) inhibitors and/or TTK/Mpsl kinase inhibitors, including pharmaceutically acceptable salts thereof, which are useful for modulating HDAC and/or TTK/Mpsl kinase activity, pharmaceutical compositions comprising these compounds, and processes for their preparation. |
| Applicant(s) |
The Regents of the University of Colorado, A Body Corporate |
| Representative Drug(s) |
D0BP8I |
Drug Info
|
IC50 = 268 nM |
[1] |
| Patent ID |
WO2014178606 |
| Title |
Novel Compounds for Selective Histone Deacetylase Inhibitors, and Pharmaceutical Composition Comprising The Same. |
| Abstract |
The present invention relates to novel urea derivatives and, more particularly, to novel urea derivatives with histone deacetylase (HDAC) inhibitory activity, isomers thereof, pharmaceutically acceptable salts thereof, their use for the preparation of a medicaments comprising the same, a pharmaceutical composition comprising the same, a treatment method using the composition, and a method for preparing novel urea derivatives. The novel urea derivatives as selective histone deacetylase (HDAC) inhibitors are effective for the treatment of histone deacetylase-mediated diseases such as malignant tumors, inflammatory diseases, rheumatoid arthritis, neurodegeneration, etc. |
| Applicant(s) |
Chong Kun Dang Pharmaceutical Corp |
| Representative Drug(s) |
D0LP1K |
Drug Info
|
IC50 = 2070 nM |
[1] |
| Patent ID |
WO2014122222 |
| Title |
Hydroxamate Derivatives Bearing Amide-Lactams As Potent Hdac Inhibitors and Their Uses As Medicaments. |
| Abstract |
The present invention relates to novel amide compounds of Formula (I), and their use as anti-tumoral and pro-apoptotic agents. The invention includes the use of such compounds in medicine, in relation to cancer disease as well as other diseases where an inhibition of HDAC is responsive, and the pharmaceutical composition containing such compounds. |
| Applicant(s) |
Sigma-Tau Industrie Farmaceutiche Riunite Spa |
| Representative Drug(s) |
D0N2DK |
Drug Info
|
IC50 < 150 nM |
[1] |
| Patent ID |
WO2013192554 |
| Title |
Substituted Tropolone Derivatives and Methods of Use. |
| Abstract |
The compositions and methods described herein relate generally to substituted tropolone derivatives, which, among other features, are useful as histone deacetylase (HDAC) inhibitors. |
| Applicant(s) |
University of Connecticut |
| Representative Drug(s) |
D0GD6R |
Drug Info
|
IC50 = 0.14 nM |
[1] |
| Patent ID |
WO2013041480 |
| Title |
New Thio Derivatives Bearing Lactams As Potent Hdac Inhibitors and Their Uses As Medicaments. |
| Abstract |
The present invention relates to novel amide compounds of Formula (I), and their use as anti-tumoral and pro-apoptotic agents. The invention includes the use of such compounds in medicine, in relation to cancer disease as well as other diseases where an inhibition of HDAC is responsive, and the pharmaceutical composition containing such compounds. |
| Applicant(s) |
Sigma-Tau Industrie Farmaceutiche Riunite Spa |
| Representative Drug(s) |
D07WAT |
Drug Info
|
IC50 < 50 nM |
[1] |
| Patent ID |
WO2013005049 |
| Title |
N- (2 -Aminophenyl) Benzamide Derivatives As Histone Deacetylase Inhibitors. |
| Abstract |
This invention relates to the discovery of novel compounds, or pharmaceutically acceptable salts thereof, which possess HDAC inhibitory activity. In particular, the compounds of the invention demonstrate selectivity towards Class I HDAC enzymes, and are accordingly expected to be useful for their anti-proliferative activity and in methods of treatment of the human or animal body, for example in preventing or inhibiting tumour growth and metastasis in cancers. The invention also relates to processes for the manufacture of the compounds defined herein, or pharmaceutically acceptable salts thereof, to pharmaceutical compositions containing them and to their use in the manufacture of medicaments for use in the production of an anti-proliferative effect in a warm-blooded animal such as man. |
| Applicant(s) |
Cancer Research Technology Limited |
| Representative Drug(s) |
D0CH8Q |
Drug Info
|
IC50 > 30000 nM |
[1] |
| United States Patent and Trademark Office (USPTO) |
| Patent ID |
US20170044185 |
| Title |
Preparation of Histone Deacetylase (Hdac) Inhibitors and Methods for Use Thereof. |
| Representative Drug(s) |
D0RA0D |
Drug Info
|
IC50 = 27.1 nM |
[1] |
| Patent ID |
US20130267542 |
| Title |
Preparation of Substituted Quinazolinones As Histone Deacetylases (Hdacs) Inhibitors. |
